This paper has explored the TGF-β pathway, and the consequences of its inhibition, in HCC cells obtained from HCC patients, with the final aim of designing biomarkers that may facilitate personalized anti-TGF-β therapies based on tumor characteristics. This evidence concerns the gene TGFB1 and neoplasm.